RET Renegades

@RetRenegades

LUNGevity’s “RET Renegades” shares resources for lung cancer patients impacted by the RET mutation. Information, resources and advocacy can be found here.

facebook.com/groups/RETlung Joined August 2020

147 Following 471 Followers 301 Posts

Latest posts 5

RET Renegades @RetRenegades Nov 20, 2023

Lessons from LIBRETTO-431 Trial in RET+ NSCLC ajmc.com/view/lessons-f… via @AJMC @RETmutation @lungcancer @lcsm

www.ajmc.com Lessons from LIBRETTO-431 Trial in RET+ NSCLC | AJMC An overview of data presented at ESMO 2023 on the LIBRETTO-431 trial of selpercatinib in RET+ NSCLC.

RET Renegades @RetRenegades Nov 11, 2023

LIBRETTO-431: Selpercatinib in RET Fusion–Positive NSCLC cancernetwork.com/view/libretto-… via @@CancerNetwrk

www.cancernetwork.com LIBRETTO-431: Selpercatinib in RET Fusion–Positive NSCLC | CancerNetwork A medical oncologist discusses data from the LIBRETTO-431 clinical trial looking at first-line selpercatinib vs chemotherapy and pembrolizumab in RET fusion–positive NSCLC.

RET Renegades @RetRenegades Oct 28, 2023

Selpercatinib Doubles Progression-Free Survival in RET-Mutated NSCLC - goo.gl/alerts/2pM9VF #GoogleAlerts #lungcancer #lcsm

www.physiciansweekly.com Selpercatinib Doubles Progression-Free Survival in RET-Mutated NSCLC | Physicians Weekly Selpercatinib doubled progression-free survival, increased response rate, and delayed pulmonary and physical deterioration in RET fusion-positive NSCLC.

RET Renegades @RetRenegades Oct 22, 2023

Retevmo Improves Progression-Free Survival in Patients with RET-Fusion Positive NSCLC curetoday.com/view/retevmo-i… via @curetoday

www.curetoday.com Retevmo Improves Progression-Free Survival in Patients with RET-Fusion Positive NSCLC | CURE Retevmo improved progression-free survival, compared with chemotherapy with or without Keytruda in patients with RET-fusion positive non-small cell lung cancer.

RET Renegades @RetRenegades Oct 12, 2023

FoundationOne CDx Is Approved to Help Identify Patients Who Are Eligible for Selpercatinib oncnursingnews.com/view/foundatio… via @@OncNursingNews

www.oncnursingnews.com FoundationOne CDx Is Approved to Help Identify Patients Who Are Eligible for Selpercatinib |... The approval of FoundationOne CDx as a companion diagnostic for selpercatinib seeks to broaden access to therapies for patients with RET fusion–positive solid tumors.